Eyebiotech Ltd.
Clinical trials sponsored by Eyebiotech Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss Results expected Sep 2026 (estimated)
- New eye drug EYE103 takes on standard treatment for Diabetes-Related vision loss Results expected Mar 2027 (estimated)
-
New eye drug EYE103 aims to restore vision in macular degeneration and vein occlusion
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called EYE103 (Restoret) in 160 people with wet age-related macular degeneration or macular edema from a branch retinal vein occlusion. Participants receive three eye injections of either a low or high dose of EYE103, spaced four week…
Phase 2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New eye drug tiespectus takes on aflibercept in major wet AMD trial
Disease control Recruiting nowThis study tests a new medicine called tiespectus (EYE201) for wet age-related macular degeneration, a leading cause of vision loss. About 960 people will receive either tiespectus or the standard treatment aflibercept via eye injections. The goal is to see if tiespectus can impr…
Phase 2/3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New eye injection could change treatment for wet AMD
Disease control Recruiting nowThis study tests a new drug called tiespectus (MK-8748) against the current standard treatment, aflibercept, for people with wet age-related macular degeneration (AMD). About 960 participants will receive injections into the eye and be followed for a year to see if tiespectus can…
Phase 2/3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC